BioWorld

July 8, 2002

Immunex Starts Second Phase III Study Of Enbrel For Psoriasis

Immunex Corp. said at the 20th annual World Congress of Dermatology Meeting in Paris that it began a second Phase III trial of Enbrel in psoriasis as the company seeks its fifth approval for the drug. (BioWorld Today) Read More

TransMolecular Fighting Cancer With The Help Of Scorpion Toxin

To Quell HIV's Inexorable Strain Variability, Alamos Lab Proposes Country-Defined AIDS Vaccines

Gerberding Named Director Of Centers For Disease Control

Holiday Notice

VaxGen, Genentech Revise Agreement On AIDS Vaccine

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Neutrophils put the brakes on fat loss

BioWorld Science

Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Peptidream reveals milestone in Alnylam collaboration

BioWorld Science

Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...